Active, not recruitingPHASE1, PHASE2NCT06015230

Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE

Studying Autosomal systemic lupus erythematosus

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Principal Investigator
xiaofeng zeng, PHD
Peking Union Medical College Hospital
Intervention
low dose GR1603 in phase Ⅰb(biological)
Enrollment
136 enrolled
Eligibility
18-70 years · All sexes
Timeline
2022 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06015230 on ClinicalTrials.gov

Other trials for Autosomal systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Autosomal systemic lupus erythematosus →

← Back to all trials